In:
Gastroenterology Research and Practice, Hindawi Limited, Vol. 2012 ( 2012), p. 1-8
Abstract:
Aim . To observe the disease activity index (DAI) and the colonic mucosa damage index (CMDI), detect the colonic mucosal expression of PPAR γ , NF- κ B, and TNF- α in rats with ulcerative colitis (UC), and to investigate the protective role of rosiglitazone in UC. Methods . Sprague-Dawley (SD) rats were divided into three groups: a control group, a rosiglitazone treatment group, and a UC model group. Rats were sacrificed on days 7, 14, 21, or 35 following administration of treatment after enema and DAI, CMDI and colonic expression of PPAR γ , NF- κ B, and TNF- α were assessed. Results . In the UC model group, DAI, CDMI and the colonic expression of NF- κ B and TNF- α increased significantly compared to the control group at all timepoints, but PPAR γ decreased significantly. Furthermore, in the rosiglitazone treatment group, DAI and CMDI decreased significantly on the 14-day, 21-day, and 35-day timepoints compared to the UC model group; the colonic expression of NF- κ B and TNF- α decreased compared to UC model group at all timepoints, but the PPAR γ expression increased significantly. Conclusions . Rosiglitazone can alleviate colonic mucosal inflammation and have the protective role on UC by upregulating PPAR γ expression and downregulating NF- κ B and TNF- α expression.
Type of Medium:
Online Resource
ISSN:
1687-6121
,
1687-630X
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2012
detail.hit.zdb_id:
2435460-0
Permalink